Value is a concept that concerns all healthcare stakeholders.
Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system
Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.
The duo hope to begin testing a new treatment within three years.
An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.
Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk
Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.
Direct-to-patient approaches can positively impact real world and late phase research programs to increase engagement, retention and data collection.
The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.
Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute
Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.
An Alliance for Safe Biologic Medicines survey shows what doctors mean by biosimilar transparency.
Angelina Jolie Pitt discloses she had her fallopian tubes and ovaries removed; the FDA's Zyprexa investigation was inconclusive; Takeda and ImmunoGen sign a $20-million deal
Nielsen data shows pharma spent $4.5 billion on DTC ads last year.
A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.
Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.
A study shows that greater access to healthcare and lower smoking rates have not made baby boomers healthier than their parents.
Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases
A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik
An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.
As global healthcare borders become increasingly blurred, the internationally mobile patient may become a standard patient segment considered in healthcare market research.
The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research
Oncology and diabetes medications are expected to be major areas of growth.
At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.
The diabetes device manufacturer will soon work with Glooko's platform.
The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.
GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.
Traditional tactics of connecting with physicians are quickly becoming obsolete.
Increased FDA scrutiny has not garnered trust for the new medications.
Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing
Amgen and Sanofi/Regeneron shared clinical trial data that shows PCSK9 inhibitors dropped LDL levels by around 60%.
The approval follows three advisory panel reviews and a complete response letter.
New data suggest Amgen's PCSK9 may reduce risks of heart attacks, Salix bidding is war too rich for Endo's blood, Actavis bipolar drug use is expanded to 10- to 17-year-olds.
J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.
Reactions to the first biosimilar approval show that marketing and education will be essential for the new category to take market share.
The research will be released as pharmacy benefit managers raise concerns about the potential costs of PCSK9 inhibitors.
The CMO of CVS Health said biosimilars could drive down prices 10% to 20% lower than current investor expectations.
The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.
The company argues its offer for Salix is superior to the terms offered by serial acquirer Valeant.
Apple now offers a way for researchers and developers to easily create clinical trial data-collection apps, revolutionizing the way that patients can participate in clinical trials.
The partners will focus on developing treatments for metabolic disorders.
Zogenix spins off painkiller business; Biogen Idec investigates the use of wearables in MS patients; J&J sues Celltrion and Hospira to delay Remicade biosimilar.
PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.
The agency's Office of Prescription Drug Promotion said a website indicated safety and effectiveness of a diagnostic tool that has not been approved by the FDA.
HCV drugs and other specialty medications drove a 13% increase in last year's prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera's drug that can reduce double chins.
Doctors tell MM&M that prescription weight-loss medications are just one component of an obesity treatment regimen.
The open-source framework uses the iPhone's apps to gather users' health information.
Novartis CEO says cost cutting is looming; Novo Nordisk presents new Saxenda weight-loss data; FDA approves Astellas Pharma's antifungal drug.
The regulator approved Novartis's Neupogen lookalike. Amgen, which markets Neupogen, has a trove of its own potential biosimilars.
FDA approves the first biosimilar, judge rules that FDA panel members had conflicts of interest, and a new venture will evaluate the effectiveness of digital health technologies.
AbbVie's $21-billion bid to acquire Pharmacyclics may insulate the drugmaker from the impact of impending Humira biosimilars.
A study by the nonprofit research group found resistance to drug switching.
The move toward digital will likely bring greater collaboration between CMOs and CIOs.
The drugmakers will explore combinations of Merck's Keytruda and Eisai's Lenvima and Halaven to treat certain cancers.
AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns
The FDA granted the drug Priority Review status just last week.
The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.
The study indicates patients discount wording that indicates the FDA has not approved supplement claims.
The agreement includes a $1-million payment.
Holding company will now focus on two health networks—FCB Health and McCann Health
NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.
Analysts say head-to-head study results could make Kyprolis the lead treatment.
Drugmakers face increasing pressure on pricing from insurers and PBMs.
The breakthrough designation therapy drug was the first for its drug class.
Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.
Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.
Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.
The organization plans to publish a scientific and a lay abstract detailing study findings
Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.
Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.
A report by the New York Times, citing a lack of an advisory committee for Vyvanse and illegal marketing lawsuits resolved last year, expressed concerns that the drug for binge-eating disorder will be overprescribed.
Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.
The EU will have access to the new medication in May.
The survey shows the use of stronger-than-morphine painkillers has jumped.
Sanofi's Lantus predecessor nabs approval; Pharmacyclics reportedly vets acquisition offers; FDA biosimilar hearing is postponed.
Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.
Smartphones drove network traffic.
The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.
J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.
The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.
Assemblyman David Chiu's bill would publish a drug's R&D and related costs.
Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.
FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.
The drugmaker wants to put the drug through additional liver-impact tests.
A MedPanel survey indicates doctors have not changed their business practices since the Open Payments database went live.
The Trustworthy Accountability of National Advertisers launched its naming-names initiative in November, but the list is empty.
Valeant grabs Salix for $10.4 billion, BMS inks to collaborations deals and Pfizer lines up to have the first treatment for a rare lung disease.
23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.
Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.
An NIH study shows possible limit to Lucentis's appeal.
The Healthcare Businesswomen's Association named Denice Torres, president of J&J's McNeil Consumer Healthcare, as its 26th Woman of the Year.
Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.
Celgene's cancer drug is now approved for newly diagnosed patients.
Scientist Cori Bargmann's Twitter history makes the nomination a bit of a surprise.
Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.
A small physician survey shows doctors think their patients have higher adherence rates than the norm.
CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.
A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- US pharma market value projected to be $550 billion in five years
- Lawmakers propose allowing pharma companies to share some off-label information
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Apple's ResearchKit: Five Guidelines for Pharma